Skip to content

EFFECTS OF PYRROLOQUINOLINE QUINONE (PQQ) SUPPLEMENTATION ON NON-ENDURANCE TRAINED ATHLETES

EFFECTS OF PYRROLOQUINOLINE QUINONE (PQQ) SUPPLEMENTATION ON METABOLIC AND PHYSIOLOGICAL ADAPTATION AT REST AND DURING SUBMAXIMAL EXERCISE IN NON-ENDURANCE-TRAINED ATHLETES: A RANDOMIZED PLACEBO-CONTROLLED TRIAL

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07148726
Enrollment
24
Registered
2025-08-29
Start date
2024-09-01
Completion date
2025-08-15
Last updated
2025-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Mitochondrial Biogenesis

Brief summary

The aim of this study was to investigate the effects of six weeks of PQQ supplementation in non-endurance-trained individuals on: 1. physiological and metabolic response during a FATmax-VO₂peak exercise test 2. resting energy expenditure, body composition and blood biomarkers (fasting glucose, lactate dehydrogenase (LDH), creatine phosphokinase (CPK) and C-reactive protein (CRP) levels) 3. blood and urine omics markers of oxidative metabolism 24 basketball players will be randomized to consume a supplement containing 20 mg/day of PQQ or placebo (PLA) during a six-week intervention. Subjects will be encouraged to maintain their usual diet and training schedule. Body composition will be assessed by dual-energy-x-ray-absorptiometry and bioimpedance analysis. Aerobic exercise performance will be evaluated through a graded exercise protocol (six 5-minutes steps followed by n 2-minutes steps until exhaustion; the initial workload was 60 watts and increased by 35 watts at the end of each step) performed on a cycle ergometer. Capillary blood lactate samples were collected at the end of each step. Blood and urine samples were also collected, and metabolomics analysis will be performed.

Interventions

DIETARY_SUPPLEMENTPyrrole Quinoline Quinone (PQQ)

Subjects will be provided with 84 capsules of the PQQ or the placebo supplement. Both supplements were in capsule form and identical in size, shape and color. The PQQ content per capsule was 10 mg. The indication was to take two capsules every evening for 6 weeks. The duration of the supplementation protocol was assessed based on a previous study (Hwang et al., 2020), while the dose was chosen according to EFSA recommendations (Turck et al., 2017).

OTHERPlacebo

Subjects were provided with 84 capsules of placebo. The indication will be to take two capsules every evening for 6 weeks.

Sponsors

University of Padova
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* 1\) Age: Participants aged between 18 and 40 years. * 2\) Body mass index (BMI): BMI within the range of 18-30 kg/m². * 4\) Physical activity: Regular engagement in non-endurance physical activities (3-4 times a week), with no participation in structured endurance training programs.

Exclusion criteria

* 1\) chronic disease; * 2\) acute illness; and * 3\) use of dietary supplements, pharmacological agents, or adherence to a hypocaloric diet.

Design outcomes

Primary

MeasureTime frameDescription
Fat oxidation during FATmax-VO₂peak exercise test using gas analyzer.6 weeksParticipants perform a graded exercise test on an electronically braked bicycle ergometer. A modified FATmax protocol is employed. After a 10-min warm-up at 50 W, the test commenced at 60 W and the workload increased by 35 W every 5 min until the participant could no longer maintain a cadence ≥60 rpm. The volume of Oxygen uptake (VO₂) and carbon dioxide production (VCO₂) per minute were recorded via a breath-by-breath gas analyzer. The average V̇O2 and V̇CO2 is extracted over the final 2 min of each stage of the test to ensure steady-state values . FatAT and carbohydrate (CHO) CHO oxidation and energy expenditure are calculated via stoichiometric equations (Jeukendrup & Wallis, 2005) and appropriate energy equivalents, with the assumption that the urinary nitrogen excretion rate was negligible. Data are analyzed workload-matched

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026